Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA12 - Novel and Combination Strategies for SCLC

    • 16:00 - 17:00
    • 8/08/2022
    • Location: Hall C8
    • Not for CME Credit
    • Type: Oral
    • Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
    • +

      Session Moderator

      16:52 - 17:00  |  Presenter: Alessandra Curioni-Fontecedro

      • Abstract

      Loading...

    • +

      Session Moderator

      16:52 - 17:00  |  Presenter: Kostas Syrigos

      • Abstract

      Loading...

    • +

      OA12.01 - Session Introduction

      16:00 - 16:01  |  Presenter: Alessandra Curioni-Fontecedro

      • Abstract

      Loading...

    • +

      OA12.02 - Session Introduction

      16:01 - 16:02  |  Presenter: Kostas Syrigos

      • Abstract

      Loading...

    • +

      OA12.03 - Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

      16:02 - 16:12  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

    • +

      OA12.04 - Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.

      16:12 - 16:22  |  Presenter: Dwight H Owen

      • Abstract

      Loading...

    • +

      OA12.05 - Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer

      16:22 - 16:32  |  Presenter: Hossein Borghaei

      • Abstract

      Loading...

    • +

      OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

      16:32 - 16:42  |  Presenter: Charles M Rudin

      • Abstract

      Loading...

    • +

      OA12.07 - Discussant

      16:42 - 16:52  |  Presenter: Virginie Westeel

      • Abstract

      Loading...

    • +

      OA12.08 - Live Q&A

      16:52 - 17:00

      • Abstract

      Loading...